These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24200760)

  • 41. Update on evidence for treatment with ranolazine in stable angina.
    Carbone F; Montecucco F; Mach F
    Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trials and tribulations associated with angina and traditional therapeutic approaches.
    Deedwania PC; Carbajal EV; Bobba VR
    Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I16-24. PubMed ID: 18373326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New agents for the therapy of angina pectoris].
    Meinertz T; Köster R
    Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
    Wenger NK; Chaitman B; Vetrovec GW
    Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ranolazine: a novel therapeutic option in chronic stable angina.
    Jose J; Jimmy B; Saravu K; Shastry BA
    Kathmandu Univ Med J (KUMJ); 2007; 5(4):596-9. PubMed ID: 18604102
    [No Abstract]   [Full Text] [Related]  

  • 48. Ranolazine: a novel agent that improves dysfunctional sodium channels.
    Pham DQ; Mehta M
    Int J Clin Pract; 2007 May; 61(5):864-72. PubMed ID: 17493093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
    Muhlestein JB; Grehan S
    Drugs R D; 2013 Sep; 13(3):207-13. PubMed ID: 23990357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The antiarrhythmic effects of ranolazine.
    Foster NJ; Haines DE
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S38-45. PubMed ID: 19898287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
    Chaitman BR; Sano J
    Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ranolazine: a potential new treatment for chronic stable angina.
    Anderson JR; Khou S; Nawarskas JJ
    Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
    Bhandari B; Subramanian L
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina.
    Arnold SV; Kosiborod M; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Spertus JA
    JAMA Intern Med; 2014 Aug; 174(8):1403-5. PubMed ID: 24887304
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
    Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction: Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes.
    Rumsfeld JS
    J Manag Care Pharm; 2006 Oct; 12(8 Suppl):S2-3. PubMed ID: 23577421
    [No Abstract]   [Full Text] [Related]  

  • 58. Ranolazine refractory angina registry: 1-year results.
    Bennett NM; Iyer V; Arndt TL; Garberich RF; Traverse JH; Johnson RK; Poulose AK; Lips A; Morgan JM; Henry TD
    Crit Pathw Cardiol; 2014 Sep; 13(3):96-8. PubMed ID: 25062392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Conservative therapy of patients with stable coronary heart disease].
    Custodis F; Laufs U
    Herz; 2012 Feb; 37(1):85-96. PubMed ID: 22331062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.